After generating ASCO fervor, Iovance unveils plans to build $75M cell therapy manufacturing plant

SourceEndpoints News
Date Published05/30/2019
Author NameNatalie Grover

Additional Reshoring Information:

Company/Division name Novartis
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2019
Capital investment ($):55
Country(ies) from which reshored:Switzerland
City reshored to:Durham
State(s) reshored to:NC
If relevant, work nearshored to:-
Product(s) reshoredspinal muscular atrophy gene therapy Zolgensma
Find Reshoring Articles